FDA Approval of Nucala for Treatment of Severe Asthma in Children
Dr. Jonathan Steinfeld, global clinical lead for the GSK mepolizumab pediatric asthma indication discusses the recent FDA approval of GSK’s Nucala (mepolizumab) the only biologic for use in children as young as 6 years old that have severe eosinophilic asthma.
Dr. Jonathan Steinfeld is the global clinical lead for the GSK mepolizumab pediatric asthma indication as well as a board-certified pediatric pulmonologist. Prior to joining GSK, Dr. Steinfeld was in academic practice for many years at St. Christopher’s Hospital for Children. At St. Christopher’s, his practice included severe asthma, cystic fibrosis, technology-dependent children, and airway malformations.
